Page last updated: 2024-08-24

halofuginone and Prostatic Neoplasms

halofuginone has been researched along with Prostatic Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Genin, O; Iluz, M; Kawada, N; Leon, O; Mor, Y; Nagler, A; Pines, M; Pinthus, JH; Sheffer, Y; Yoshizato, K1
Barak, V; Eshhar, Z; Gavish, Z; Nagler, A; Pines, M; Pinthus, JH; Ramon, J1

Other Studies

2 other study(ies) available for halofuginone and Prostatic Neoplasms

ArticleYear
Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Synergism; Fibroblasts; Humans; Male; Mice; Mice, Nude; Muscles; Myoblasts; Piperidines; Prostatic Neoplasms; Quinazolinones; Taxoids; Tumor Cells, Cultured; Wilms Tumor

2007
Growth inhibition of prostate cancer xenografts by halofuginone.
    The Prostate, 2002, May-01, Volume: 51, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Apoptosis; Collagen Type I; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Phenotype; Piperidines; Prostatic Neoplasms; Quinazolines; Quinazolinones

2002